1ISG-005 Analysis of pharmaceutical interventions in a multidisciplinary telepharmacy programme

<h3>Background and Importance</h3> Telepharmacy improves access to treatments for frail patients with mobility limitations. <h3>Aim and Objectives</h3> To assess pharmaceutical interventions (PI) in a multidisciplinary telepharmacy programme (MTP). <h3>Material and Methods</h3> MTP included a healthcare team composed of hospital pharmacists, nurses, trained pharmacy technicians and nursing technicians. Patients included presented clinically stable chronic disease on treatment for &gt;3 months, adequate tolerance to medication, adherence &gt;90% and difficulty travelling to hospital. Pharmacists checked the pharmacotherapeutic context of this entire population. Patients were contacted by telephone (pharmacotherapeutic interview) 1-week before the drugs were sent to primary care centres every 2–3 months. PI between February and September 2024 were evaluated. Farmatools application and clinical history were used to obtain data for analysis: patients in MTP, distribution of PI in patients, therapies, prescribing medical departments and types of PI. <h3>Results</h3> MTP included 516 patients. PI were 247, which were distributed among 157 patients. The most frequently involved therapies were: adalimumab 40 mg (N = 41; 16.6%), etanercept 50 mg (N = 29; 11.7%), tofacitinib 5 mg (N = 16; 6.5%), secukinumab 300 mg (N = 10; 4%) and dimethylfumarate 240 mg (N = 7; 2.8%). The medical departments with the most PI were Internal Medicine (N = 88; 35.6%), Dermatology (N = 46; 18.6%), Pneumology (N = 29; 11.7%), Neurology (N = 22; 8.9%) and Infectious Diseases (N = 15; 6.1%). Types of PI: close pharmacotherapeutic follow-up due to lack of medical follow-up (N = 94; 38.1%), monitoring or information on treatment adherence (N = 51; 20.6%), closer monitoring due to risk of inadequate therapy effectiveness (N = 29; 11.7%), reporting adverse event information (N = 24; 9.7%), review and information on drug interactions (N = 17; 6.9%), information on drug administration (N = 12; 4.9%) and others (N = 20; 8.1%). <h3>Conclusion and Relevance</h3> Numerous PI were developed in MTP. Adalimumab 40 mg and etanercept 50 mg were the most frequently intervened therapies. The medical departments most frequently involved were Internal Medicine and Dermatology. The most common PI were close pharmacotherapeutic follow-up due to lack of medical follow-up and monitoring/provision of information on treatment adherence. Some PI addressed ineffectiveness, adverse events, interactions and drug administration. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest